<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 5.1.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body text="#000000" bgcolor="#ffffff" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt;"><font style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</font></div>
      <div style="text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> <br>
      </div>
      <div style="text-align: center; font-size: 12pt;"><font style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">WASHINGTON, D.C. 20549</font></div>
      <div style="text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> <br>
      </div>
      <div style="text-align: center; font-size: 18pt;"><font style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">FORM 8-K</font></div>
      <div style="text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> <br>
      </div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold;">CURRENT REPORT</font></div>
      <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold;">Date of Report </font><font style="font-size: 10pt;
            font-family: &quot;Times New Roman&quot;; font-weight: bold;">(Date of earliest event reported):</font><font style="font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</font><font style="font-size: 10pt; font-family: &quot;Times New
            Roman&quot;; font-weight: bold;">March 26, 2019</font></font></div>
      <div><br>
      </div>
      <div style="text-align: center; font-size: 24pt;"><font style="font-family: &quot;Times New Roman&quot;;"><font style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">Rexahn Pharmaceuticals, Inc.</font></font></div>
      <div style="text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> <br>
      </div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: &quot;Times New Roman&quot;;">(Exact Name of Registrant as Specified in its Charter)</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <table cellspacing="0" cellpadding="0" border="0" align="center" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse;" id="z55144f7fe6854262bc3d1c005ed61c77">

          <tr>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">DELAWARE</font></font></div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">001-34079</font></div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">11-3516358</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top;">
              <div>
                <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(State or other jurisdiction of Incorporation)</font></div>
              </div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(Commission File Number)</font></div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-family: 'Times New Roman', serif; font-size: 1pt;"><font style="font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</font></font><font style="font-size: 10pt; font-family: 'Times New
                  Roman';">(I.R.S. Employer Identification No.)</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse;" id="z40f0c12a0c5f46a6833124766c257dba">

          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">15245 Shady Grove Road, Suite 455</font></div>
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Rockville, MD</font></font></div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">20850</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(Address of principal executive offices)</font></div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(Zip Code)</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Registrant&#8217;s telephone number, including area code:&#160; (240) 268-5300</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
          following provisions:</font></div>
      <div><br>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="ze62d8cf9fca94e38b644aeb6978b935c">

              <tr>
                <td style="width: 18pt; vertical-align: top; align: right;">&#9744;</td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
        </div>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="zb5e294f68264451aa726cddad7fa8293">

              <tr>
                <td style="width: 18pt; vertical-align: top; align: right;">&#9744;</td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
        </div>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="z643347b02c1649d7885150fee483f6e8">

              <tr>
                <td style="width: 18pt; vertical-align: top; align: right;">&#9744;</td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
        </div>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="z24e03f7b169f4c6d9970a8a473e87ef3">

              <tr>
                <td style="width: 18pt; vertical-align: top; align: right;">&#9744;</td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)
          or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div>
      <div style="text-align: right; text-indent: 36pt; margin-left: 252pt;"><font style="font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Emerging growth company</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#9744;</div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
          revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#9744;</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: left;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="font-size:
          10pt; font-family: 'Times New Roman';"> </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="z720c252edc4443febc7798889cb548ae">

              <tr>
                <td style="width: 45pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Item 5.07.</font></td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Submission of Matters to a Vote of Security Holders.</font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">On March 26, 2019, Rexahn Pharmaceuticals, Inc. (the &#8220;Company&#8221;) held a Special Meeting of Shareholders (the &#8220;Special Meeting&#8221;). As of February 11, 2019,
          the record date for the Special Meeting, there were 48,277,420 shares of the Company&#8217;s common stock, par value $0.0001 (the &#8220;Common Stock&#8221;), issued and outstanding and entitled to vote on the proposals presented at the Special Meeting. Set forth
          below are the final voting results for each of the proposals submitted to a vote of the Company&#8217;s shareholders at the Special Meeting.</font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Proposal 1. Amendment to the Company&#8217;s Amended and Restated Certificate of
              Incorporation</u></font></font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u> <br>
            </u></font></font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">The Company&#8217;s shareholders approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse
          stock split of the Company&#8217;s common stock at a ratio within the range of 1:5 to 1:15, as determined by the Board of Directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Board of
          Directors in its sole discretion. The voting on this proposal is set forth below:</font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <table cellspacing="0" cellpadding="0" border="0" align="center" style="border-collapse: collapse; width: 60%; font-family: 'Times New Roman'; font-size: 10pt;" id="z0a8b3b19a43b4303b1ff00ef19b69d3a">

          <tr>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">For</font></div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Against</font></div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Abstentions</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">24,922,768</font></div>
            </td>
            <td style="width: 20%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">12,689,599</font></div>
            </td>
            <td style="width: 20%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">516,962</font></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">There were no broker non-votes for Proposal 1.</font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Proposal 2. Authorization to Adjourn the Special Meeting</u></font></font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u> <br>
            </u></font></font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">The Company's shareholders approved the proposal to adjourn the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if
          there are not sufficient votes to approve Proposal 1. The voting on this proposal is set forth below:</font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <table cellspacing="0" cellpadding="0" border="0" align="center" style="border-collapse: collapse; width: 60%; font-family: 'Times New Roman'; font-size: 10pt;" id="z4b8e55a820734cbfb4b61b27017d098c">

          <tr>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">For</font></div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Against</font></div>
            </td>
            <td style="width: 20%; vertical-align: bottom;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Abstentions</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">25,249,294</font></div>
            </td>
            <td style="width: 20%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">12,276,984</font></div>
            </td>
            <td style="width: 20%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">603,049</font></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">There were no broker non-votes for Proposal 2.</font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Adjournment of the Special Meeting was not necessary or appropriate because there were sufficient votes in favor of Proposal 1.</font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">SIGNATURE</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
          undersigned hereunto duly authorized.</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%; border-collapse: collapse;" id="zb1bb8ae6dcf245c181756e6c3c027192">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">REXAHN PHARMACEUTICALS, INC.</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Date: March 26, 2019</font></div>
            </td>
            <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">/s/ Douglas J. Swirsky</font></font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Douglas J. Swirsky</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">President and Chief Executive Officer</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "form8k.htm", "description": "8-K", "secsgml_size_bytes": 24460}]
{"company-data": {"conformed-name": "REXAHN PHARMACEUTICALS, INC.", "cik": "0001228627", "assigned-sic": "2834", "irs-number": "113516358", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-34079", "film-number": "19705460"}, "business-address": {"street1": "15245 SHADY GROVE ROAD, SUITE 455", "city": "ROCKVILLE", "state": "MD", "zip": "20850", "phone": "2402685300"}, "mail-address": {"street1": "15245 SHADY GROVE ROAD, SUITE 455", "city": "ROCKVILLE", "state": "MD", "zip": "20850"}, "former-company": {"former-conformed-name": "CORPORATE ROAD SHOW DOT COM INC", "date-changed": "20030423"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported):
March 26, 2019
Rexahn Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
DELAWARE
001-34079
11-3516358
(State or other jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
15245 Shady Grove Road, Suite 455
Rockville, MD
20850
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:  (240) 268-5300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
          following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
          or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
          revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ☐
Item 5.07.
Submission of Matters to a Vote of Security Holders.
On March 26, 2019, Rexahn Pharmaceuticals, Inc. (the "Company") held a Special Meeting of Shareholders (the "Special Meeting"). As of February 11, 2019,
          the record date for the Special Meeting, there were 48,277,420 shares of the Company's common stock, par value $0.0001 (the "Common Stock"), issued and outstanding and entitled to vote on the proposals presented at the Special Meeting. Set forth
          below are the final voting results for each of the proposals submitted to a vote of the Company's shareholders at the Special Meeting.
Proposal 1. Amendment to the Company's Amended and Restated Certificate of
              Incorporation
The Company's shareholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect a reverse
          stock split of the Company's common stock at a ratio within the range of 1:5 to 1:15, as determined by the Board of Directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Board of
          Directors in its sole discretion. The voting on this proposal is set forth below:
For
Against
Abstentions
24,922,768
12,689,599
516,962
There were no broker non-votes for Proposal 1.
Proposal 2. Authorization to Adjourn the Special Meeting
The Company's shareholders approved the proposal to adjourn the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if
          there are not sufficient votes to approve Proposal 1. The voting on this proposal is set forth below:
For
Against
Abstentions
25,249,294
12,276,984
603,049
There were no broker non-votes for Proposal 2.
Adjournment of the Special Meeting was not necessary or appropriate because there were sufficient votes in favor of Proposal 1.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
          undersigned hereunto duly authorized.
REXAHN PHARMACEUTICALS, INC.
Date: March 26, 2019
/s/ Douglas J. Swirsky
Douglas J. Swirsky
President and Chief Executive Officer